Online Program Home
My Program

CC = Vancouver Convention Centre   F = Fairmont Waterfront Vancouver
* = applied session       ! = JSM meeting theme

Activity Details

301 Tue, 7/31/2018, 8:30 AM - 10:20 AM CC-West 213
SPEED: Statistics for Biopharmaceutical Studies — Contributed Speed
Biopharmaceutical Section, Section on Bayesian Statistical Science
Chair(s): Michael M. Hoffman, Princess Margaret Cancer Centre/University of Toronto
Poster Presentations for this session.
8:35 AM Probabilistic Modeling of Sleep and Awake States in Alzheimer's Disease

Cici Bauer, Pfizer, Inc; Charmaine Demanuele, Pfizer, Inc. ; Dmitri Volfson, Pfizer
8:40 AM Integrative Statistical Analysis Pipeline for RNA-Seq and NanoString with Application to Gene Expression Data of Cancer Patients

Jeea Choi, Novartis Pharmaceuticals; Catarina D. Campbell, Novartis Institutes for BioMedical Research; Xiaoshan Wang, Novartis Pharmaceuticals; He Wei, Novartis Pharmaceuticals; Robinson Douglas, Novartis Pharmaceuticals; Stephane Wong, Novartis Pharmaceuticals; Bin Fu, Novartis Pharmaceuticals; Rebecca Leary, Novartis Institutes for BioMedical Research; Kavitha Venkatesan, Novartis Institutes for BioMedical Research; Ying A Wang, Novartis Pharmaceuticals
8:45 AM Bridging Information Between Dose-Response Curves Across Populations in Early Phase Clinical Trials
Moreno Ursino, Inserm DR PA 6
8:50 AM A Simultaneous PK/PD Model for Muscle Relaxant Using Muscle Twitch Counts

Elizabeth Sigworth; Matthew S Shotwell, Vanderbilt University

Gang Jia, Merck & Co.
9:00 AM Conditional Power Calculation for the Interim Monitoring of Cluster-Randomized Trials with Interval-Censored Endpoints

Kaitlyn Cook, Harvard University; Rui Wang, Harvard Pilgrim HealthCare Institute
9:05 AM Explore Modified Organ Dysfunction Score System to Improve the Prediction of Survival

Grace Zhang, GSK
9:10 AM Discovering Biomarkers Jointly Modeled with Multiple Efficacy Variables in Early Phase Clinical Trials

Danni Yu, Eli Lilly and Company
9:15 AM Extended Rank Tests for Analyzing Recurrent Event Data

Qiang Zhao; Mark Chang, Veristat; Michael LaValley, Boston University; Joseph M. Massaro, Boston University; Bin Zhang, Seqirus; Kathryn Lunetta, Boston University
9:20 AM A Study in the Use of Unsupervised Random Forest in the Analysis of Data Sets Composed of Categorical Variables/Features

Nelson Lee Afanador, Merck; Richard Baumgartner, Merck; Dai Feng, Merck
9:30 AM A Statistical Evaluation of Cardiovascular Measurements Collected via Mobile Health Technology and Traditional Tools
Qinlei Huang, Merck; Lori Mixson, Merck
9:35 AM Method for Evaluating Longitudinal Follow-Up Frequency: Application to Dementia Research

Leah Suttner, University of Pennsylvania; Sharon X Xie, University of Pennsylvania
9:40 AM Performance Comparison of Post-Hoc Subgroup Search Algorithms for Clinical Trials

Victor Talisa, University of Pittsburgh; (Joyce) Chung-Chou H. Chang, University of Pittsburgh
9:45 AM Relationship Between ORR, PFS and OS in Patients Treated with Anti-PD1/PDL1 Therapies

Jiabu Ye, AstraZeneca; Pralay Mukhopadhyay, Astrazeneca; Xiang Ji, AstraZeneca
9:50 AM Real-Time Study Milestone Projection in Clinical Trials with Time-To-Event Endpoints

Yanping Liu, Merck & Co.; Gang Jia, Merck & Co.
9:55 AM Sensitivity to Infusion and Blood Draw Time Recording Errors in Pharmacokinetic Modeling

Hannah Weeks, Vanderbilt University; Matthew S Shotwell, Vanderbilt University
10:00 AM A Testing Paradigm for Earl Biomedical Research with Many Correlated Tests

Robert Montgomery; Jonathan D Mahnken, University of Kansas Medical Center